Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
A new strategy for emergency anticoagulant treatment for patients with acute myocardial infarction has been put in place by a team led by Philippe-Gabriel Steg at Inserm Unit 698 (Haemostasis, Bioengineering, Immunopathology and Cardiovascular Remodelling), at Hopital Bichat, AP-HP, Universite Paris Diderot). These results from the EUROMAX clinical trial are published in The New England Journal of Medicine.
Myocardial infarction, commonly called "heart attack," remains the leading cause of death worldwide, and affects nearly 100,000 individuals a year in France. The reference treatment is urgent dilation of the arteries to enable the blood to circulate to the heart (This medical procedure is known as primary angioplasty). Angioplasty requires injectable anticoagulant treatment for which several options are available.
An international team led by Philippe-Gabriel Steg at Inserm Unit 698 (Haemostasis, Bioengineering, Immunopathology and Cardiovascular Remodelling), at HĂ´pital Bichat, AP-HP, UniversitĂ© Paris Diderot) has just reported the results of a large international clinical trial carried out in 9 European countries, on nearly 2,200 patients, testing the administration of anticoagulant treatment prior to arrival in hospital by emergency teams and the emergency ambulance service, and comparing the two strategies, in The New England Journal of Medicine . The first is based on heparin (traditional treatment), the other on a more specific anticoagulant, bivalirudin. One of the main drawbacks of these anticoagulant treatments is the risk of associated haemorrhage. "By dilating the arteries, we also thin the blood, with the risk of uncontrolled bleeding if haemorrhage occurs," explains Philippe-Gabriel Steg.
After 30 days of monitoring, bivalirudin reduced the risk of death or serious bleeding by 8.5 to 5.1% and the risk of death, myocardial infarction or major bleed by 9.2 to 6.6%, compared with the strategy using heparin.
This benefit was mainly linked to the reduction in serious bleeding, at the cost of an increased risk of stent thrombosis . "The benefits are robust and consistent for all sub-groups tested, and in particular, consistent regardless of the type of oral anti-clotting treatment or route of arterial access used for angioplasty (via the radial or femoral artery)," explains Philippe-Gabriel Steg.
These results open up the way to using bivalirudin as an anticoagulant at the pre-hospital phase of myocardial infarction in patients being urgently transferred. They represent progress in the treatment of myocardial infarction that can be immediately used.
The EUROMAX trial was conducted with the support of The Medicines Company. It is registered in Clinical Trials.gov, under the reference NCT01087723.
Bivalirudin Started during Emergency Transport for Primary PCI. Steg PG, van 't Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, Ten Berg J, Van Grunsven P, Eggink GJ, Nibbe L, Zeymer U, Campo dell' Orto M, Nef H, Steinmetz J, Soulat L, Huber K, Deliargyris EN, Bernstein D, Schuette D, Prats J, Clayton T, Pocock S, Hamon M, Goldstein P, for the EUROMAX Investigators* The New England Journal of Medicine 30 October 2013 DOI: 10.1056/NEJMoa1311096
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Cardiovascular / Cardiology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
de la re, INSERM (Institut national de la santĂ© et. "Bivalirudin for heart attack soon to be available for emergency teams and ambulances." Medical News Today. MediLexicon, Intl., 1 Nov. 2013. Web.
11 Dec. 2013. <http://www.medicalnewstoday.com/releases/268153>
de la re, I. (2013, November 1). "Bivalirudin for heart attack soon to be available for emergency teams and ambulances." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/268153.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.